sim0237
mAbexperimentalBi-specific
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 8, 2023 (NCT05781360)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Interleukin-15INHIBITOR
IL15 inhibitor
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06186414 | Phase 1 | Jan 23, 2024 | Shanghai Xianxiang Medical Technology Co., Ltd., Simcere Pharmaceutical Co., Ltd |
| NCT05781360 | Phase 1 | Mar 8, 2023 | Shanghai Xianxiang Medical Technology Co., Ltd., Simcere Pharmaceutical Co., Ltd |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Shanghai Xianxiang Medical Technology Co., Ltd. | For profit | 2 | 0 | 1 | 2023 |
| Simcere Pharmaceutical Co., Ltd | For profit | 2 | 2 | 1 | 2023 |
2 organizations
Page 1 / 1